

Complete Summary

GUIDELINE TITLE

ASGE guideline: guidelines for endoscopy in pregnant and lactating women.

BIBLIOGRAPHIC SOURCE(S)

Oureshi WA, Rajan E, Adler DG, Davila RE, Hirota WK, Jacobson BC, Leighton JA, Zuckerman MJ, Hambrick RD, Fanelli RD, Baron T, Faigel DO. ASGE guideline: guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc 2005 Mar; 61(3): 357-62. [36 references] [PubMed](#)

GUIDELINE STATUS

This is the current release of the guideline.

COMPLETE SUMMARY CONTENT

SCOPE
 METHODOLOGY - including Rating Scheme and Cost Analysis
 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
 CONTRAINDICATIONS
 QUALIFYING STATEMENTS
 IMPLEMENTATION OF THE GUIDELINE
 INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
 CATEGORIES
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Pregnancy

Lactation

Gastrointestinal (GI) disorders including:

- Significant or continued gastrointestinal bleeding
- Severe or refractory nausea and vomiting or abdominal pain
- Dysphagia or odynophagia
- Colon mass
- Severe diarrhea

- Biliary pancreatitis, choledocholithiasis, or cholangitis
- Biliary or pancreatic ductal injury

GUIDELINE CATEGORY

Evaluation
Management

CLINICAL SPECIALTY

Gastroenterology
Obstetrics and Gynecology

INTENDED USERS

Physicians

GUIDELINE OBJECTIVE(S)

To provide guidelines for the use of endoscopy in pregnant and lactating women

TARGET POPULATION

Pregnant or lactating women who require endoscopy

INTERVENTIONS AND PRACTICES CONSIDERED

Procedures

1. Esophagogastroduodenoscopy (EGD)
2. Colonoscopy
3. Endoscopic retrograde cholangiopancreatography (ERCP)
4. Electrocautery and hemostasis

Precautions

1. Placement of patient in "pelvic tilt" or left lateral position
2. Maternal-fetal monitoring
3. Consultation with obstetrician before endoscopy

Pharmacologic Therapy

1. Meperidine
2. Fentanyl
3. Naloxone
4. Benzodiazepines
 - Diazepam (considered, but not recommended)
 - Midazolam (avoid in first trimester)
5. Flumazenil
6. Propofol

7. Simethicone
8. Glucagon
9. Topical anesthetics
 - Lidocaine (avoid swallowing)
10. Antibiotics
 - Safe in pregnancy
 - Penicillins
 - Cephalosporins
 - Erythromycin (except estolate)
 - Clindamycin
 - Safe while breast-feeding
 - Penicillins
 - Cephalosporins
 - Erythromycin
 - Tetracycline
 - Nitrofurantoin (except in infants with glucose-6-phosphate dehydrogenase deficiency)
 - Avoid in pregnancy
 - Quinolones (also avoid during breast-feeding)
 - Streptomycin
 - Tetracyclines
 - Avoid in first trimester of pregnancy and during breast-feeding
 - Metronidazole
 - Avoid in third trimester of pregnancy
 - Sulfonamides (also avoid during breast-feeding)
 - Nitrofurantoin
11. Colon-cleansing agents
 - Polyethylene glycol (PEG) electrolyte isotonic cathartic solutions
 - Sodium phosphate preparations
 - Tap water enemas

MAJOR OUTCOMES CONSIDERED

Not stated

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)
 Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

In preparing this guideline, a MEDLINE literature search was performed and additional references were obtained from the bibliographies of the identified articles and from recommendations of expert consultants.

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Expert Consensus

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Guidelines for appropriate utilization of endoscopy are based on a critical review of the available data and expert consensus.

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Not stated

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not applicable

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Level of Evidence (A-C) definitions are provided at the end of the "Major Recommendations" field.

In situations where therapeutic intervention is necessary, endoscopy offers a relatively safe alternative to radiologic or surgical intervention. The main indications for endoscopy in pregnancy are outlined in the table below titled "Indications for Endoscopy in Pregnancy." General principles that apply to endoscopy in pregnancy are shown in the table below titled "General Principles Guiding Endoscopy in Pregnancy."

Indications for Endoscopy in Pregnancy	
<ol style="list-style-type: none"> 1. Significant or continued gastrointestinal (GI) bleeding 2. Severe or refractory nausea and vomiting or abdominal pain 3. Dysphagia or odynophagia 4. Strong suspicion of colon mass 5. Severe diarrhea with negative evaluation 6. Biliary pancreatitis, choledocholithiasis, or cholangitis 7. Biliary or pancreatic ductal injury 	
General Principles Guiding Endoscopy in Pregnancy	
<ol style="list-style-type: none"> 1. Always have a strong indication, particularly in high-risk pregnancies 2. Defer endoscopy to second trimester whenever possible 3. Use lowest effective dose of sedative medications 4. Wherever possible, use category A or B drugs 5. Minimize procedure time 6. Position pregnant patients in left pelvic tilt or left lateral position to avoid vena caval or aortic compression 7. Presence of fetal heart sounds should be confirmed before sedation is begun and after the endoscopic procedure 8. Obstetric support should be available in the event of a pregnancy-related complication 9. Endoscopy is contraindicated in obstetric complications such as placental abruption, imminent delivery, ruptured membranes, or eclampsia 	

Safety of Commonly Used Medications for Endoscopy during Pregnancy

The U.S. Food and Drug Administration (FDA) lists 5 categories of drugs with regard to safety during pregnancy (see table below). There are no category A drugs used for endoscopy. For use during endoscopic procedures, category B and, when necessary, category C drugs are recommended. Category D drugs may be used when the benefits clearly outweigh the risks. These categories are of limited value for determining the safety of one-time use; therefore, consultation with an obstetrician regarding medication should be considered. For most procedures, the level of sedation should be anxiolysis or moderate sedation. If deep sedation is necessary, it should be administered by an anesthesiologist.

Food and Drug Administration Categories for Drugs Used in Pregnancy	
Category	Description
A	Adequate, well-controlled studies in pregnant women have not shown an

Food and Drug Administration Categories for Drugs Used in Pregnancy	
Category	Description
	increased risk of fetal abnormalities
B	Animal studies have revealed no evidence of harm to the fetus; however, there are no adequate and well-controlled studies in pregnant women or Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus
C	Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women or No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women
D	Studies, adequate well-controlled or observational, in pregnant women have demonstrated a risk to the fetus; however, the benefits of therapy may outweigh the potential risk
X	Studies, adequate well-controlled or observational, in animals or pregnant women have demonstrated positive evidence of fetal abnormalities; use of the product is contraindicated in women who are or may become pregnant

Meperidine (Category B)

Meperidine does not appear to be teratogenic as reported in two large studies. It is preferred over morphine (category C), which crosses the fetal blood-brain barrier more rapidly, and fentanyl (category C).

Fentanyl (Category C)

This narcotic has a rapid onset of action and a shorter patient recovery time than meperidine. Fentanyl is not teratogenic but was embryocidal in rats. It appears safe in humans when given in low doses typical for endoscopy.

Naloxone (Category B)

This rapidly acting opiate antagonist crosses the placenta within 2 minutes of intravenous administration. It does not appear to be teratogenic. Its use is contraindicated in mothers dependent on opiates, because it can precipitate opiate-withdrawal symptoms. It should only be used in respiratory depression, hypotension, or unresponsiveness in a closely monitored setting. The potential for re-sedation as naloxone is metabolized should be recognized.

Benzodiazepines (Category D)

Sustained use of diazepam during early pregnancy (first trimester) has been associated with cleft palate and, when used later in the pregnancy, neurobehavioral disorders, although this association is challenged by some investigators. Diazepam should not be used for sedation in pregnant women.

Midazolam, although also category D, has not been reported to be associated with congenital abnormalities. Midazolam is the preferred benzodiazepine when sedation with meperidine is inadequate. Avoid the use of midazolam in the first trimester if possible.

Flumazenil (Category C)

Little is known of the safety profile of this benzodiazepine antagonist. Although it is not teratogenic in rats and mice, it does produce subtle neurobehavioral changes in male offspring of rats exposed to the drug in utero.

Propofol (Category B)

In the pregnant patient, it is recommended that propofol be administered by an anesthesiologist, because of its narrow therapeutic index and the importance of close monitoring. Safety in the first trimester has not been well studied.

Simethicone (Category C)

This is a category C drug because of a lack of studies, but it commonly is given to pregnant women and probably is safe.

Glucagon (Category B)

Glucagon is an antispasmodic, commonly used during endoscopic retrograde cholangiopancreatography (ERCP) that is not contraindicated during pregnancy.

Topical Anesthetics

Topical anesthetics (e.g., lidocaine [category B]), often are used to decrease the gag reflex and to make intubation easier. One study showed no fetal malformations in 293 infants with first trimester exposure. It may be prudent to ask the patient to gargle and to spit out the drug instead of swallowing it when its use is deemed necessary.

Antibiotics

Most antibiotics can be safely used in pregnancy, and the indications for their prophylactic use are similar to those in nonpregnant patients. However, some antibiotics are contraindicated because of adverse fetal effects, and others are safe in only certain trimesters. The table below summarizes the recommendations at present. Further details can be obtained from sources (e.g., *Drugs in Pregnancy and Lactation*).

Antibiotic Safety in Pregnancy			
Safe in Pregnancy	Avoid in Pregnancy	Avoid in First Trimester	Avoid in Third Trimester
Penicillins Cephalosporins Erythromycin (except	Quinolones Streptomycin Tetracyclines	Metronidazole	Sulfonamides Nitrofurantoin

Antibiotic Safety in Pregnancy			
Safe in Pregnancy	Avoid in Pregnancy	Avoid in First Trimester	Avoid in Third Trimester
estolate) Clindamycin			

Colon-Cleansing Agents

The safety of polyethylene glycol (PEG) electrolyte isotonic cathartic solutions has not been studied in pregnancy. Polyethylene glycol solutions are category C. Sodium phosphate preparations (category C) may cause fluid and electrolyte abnormalities and should be used with caution. Tap water enemas may be sufficient for flexible sigmoidoscopy.

Procedures

For all endoscopy procedures, it is suggested that the patient who is in the second or third trimester not lie on her back while waiting for the procedure or afterward in recovery. This is because the pregnant uterus can compress the aorta and/or the inferior vena cava (IVC), causing maternal hypotension and decreased placental perfusion. By placing a wedge or pillow under the right hip, a "pelvic tilt" is created to prevent this. The patient also may sit up if she so prefers, because this will prevent inferior vena cava compression. Most procedures are done in the left lateral position where this is not an issue. Pregnant patients also are more likely to aspirate gastric contents or secretions than nonpregnant ones. In addition to the usual patient monitoring, maternal-fetal monitoring should be performed as described above in the table titled "General Principles Guiding Endoscopy in Pregnancy." Consultation with an obstetrician should be considered before endoscopy.

Procedural Considerations in Pregnancy

Upper endoscopy is performed as in nonpregnant patients. Case series and case-control studies suggest it is safe and effective. In a case-control study of 83 upper endoscopies (esophagogastroduodenoscopy [EGD]) performed during pregnancy, the diagnostic yield for upper-GI bleeding was 95%. In this study, esophagogastroduodenoscopy did not induce premature labor and no congenital malformations were reported. Studies assessing the safety of colonoscopy in pregnancy involve extremely small numbers, limiting the ability to detect uncommon adverse outcomes. In late pregnancy, patients should not be placed supine or prone during colonoscopy. If external abdominal pressure is required, great care should be taken to apply mild force and to direct it away from the uterus.

ERCP

ERCP should only be used when therapeutic intervention is intended. Biliary pancreatitis, choledocholithiasis, or cholangitis are the usual indications, and can lead to fetal loss if not treated properly. Several studies have confirmed the safety of ERCP in pregnancy. The fetus should be shielded from the ionizing radiation. Lead shields are placed under the pelvis and lower abdomen, remembering that

the x-ray beam originates from beneath the patient. Measuring radiation exposure to the area of the uterus also should be considered. Radiation exposure is reduced by collimating the beam to the area of interest. Use brief "snapshots" of fluoroscopy to confirm cannula position and common bile-duct stones. Avoid taking hardcopy x-ray films, because these involve additional radiation. Consultation with a radiologist or a hospital radiation safety officer may be useful in minimizing the radiation exposure to the fetus. With thoughtful precaution, the fetal exposure is well below the 5- to 10-rad level considered to be of concern for radiation-induced teratogenesis. Only experienced endoscopists should attempt the procedure.

Electrocautery and Hemostasis

Amniotic fluid can conduct electrical current to the fetus. The grounding pad should be placed in such a position that the uterus is not between the electrical catheter and the grounding pad. Bipolar electrocautery should be used to minimize this risk of "stray" currents going through the fetus. Although electrocautery is relatively safe when used for sphincterotomy and hemostasis, polyp removal should be postponed until after pregnancy.

Epinephrine is pregnancy category C and causes a decrease in uterine blood flow. Its safety, when used as an endoscopic injectant, has not been studied, although, when given in low-dose combinations for analgesia, it is safe. Its use for hemostasis should balance the benefits with the potential risks.

Breast-Feeding

Indications and Contraindications

Diagnostic and therapeutic endoscopy in lactating women do not vary in terms of indication, preprocedural preparation, procedural monitoring, radiation exposure, and endoscopic equipment. Caution needs to be exercised in the use of certain medications, because these drugs may be transferred to the infant through breast milk. In these instances, where there is a concern regarding the transfer to the infant, the woman should be advised to pump her breast milk and discard it, with the timing dependent upon the agent of concern.

Sedation and Analgesia

The sensitivity to and risks of sedation in a lactating woman is similar to any adult.

Midazolam. Midazolam is excreted in breast milk. However, a study of 12 women receiving 15 mg midazolam orally found no measurable concentrations (<10 nmol/L) in milk samples obtained 7 hours after ingestion. Additional investigations on two women showed that midazolam and its metabolite, hydroxymidazolam, were undetectable after 4 hours. The American Academy of Pediatrics considers the effects of midazolam unknown on the nursing infant, but the drug may be of concern. Based on these data, it would be advisable to recommend withholding nursing of the infant for at least 4 hours after administration of midazolam.

Fentanyl. Fentanyl is excreted in breast milk, but the concentrations are too low to be pharmacologically significant and fall to undetectable levels by 10 hours after administration. The American Academy of Pediatrics considers fentanyl to be compatible with breast-feeding.

Meperidine. Meperidine is concentrated in breast milk and may be detectable up to 24 hours after administration. Studies have suggested that meperidine can be transferred to the breast-fed infant and may have neurobehavioral effects. Whereas, the American Academy of Pediatrics classified meperidine as compatible with breast-feeding in their 1983 statement, it may be reasonable to use an alternative (e.g., fentanyl) where possible.

Propofol. Propofol is excreted in breast milk, with maximum concentrations at 4 to 5 hours after administration. The effects of small oral doses of propofol on the infant are unknown. Continued breast-feeding after propofol exposure is not recommended, although the period of prohibition has yet to be determined.

Naloxone and flumazenil. The safety of naloxone and flumazenil in this setting is unknown.

Antibiotics

Penicillins and cephalosporins. Penicillins and cephalosporins are excreted in breast milk in trace amounts and are considered compatible with breast-feeding.

Ofloxacin and ciprofloxacin. Ofloxacin and ciprofloxacin are excreted in breast milk, and their toxicity has not been well studied.

Quinolones. As there is a potential for arthropathy in the infant, quinolones should be avoided.

Sulfonamides. Sulfonamides are contraindicated when nursing infants younger than 2 months because of the risk of kernicterus. It is recommended that sulfonamides be avoided in infants that are ill, premature, and glucose-6-phosphate dehydrogenase deficient. The safety of commonly used antibiotics is summarized in Table 5 of the original guideline document.

Summary

For the following points: (A), Prospective controlled trials. (B), observational studies. (C), Expert opinion.

- Endoscopy during pregnancy should only be done when there is a strong indication and should be postponed to the second trimester whenever possible. (C)
- The close involvement of obstetrical staff is recommended. (C)
- The degree of maternal and fetal monitoring needs to be individualized. (C)
- For procedural sedation during pregnancy, meperidine alone is preferred, followed by small doses of midazolam as needed. (C)
- If deep sedation is needed, it should be administered by an anesthesiologist. (C)

- Esophagogastroduodenoscopy and colonoscopy generally are safe during pregnancy. (C)
- ERCP generally is safe, provided care is taken to minimize radiation exposure to the fetus (B) and risks to the mother. (C)
- Bipolar electrocautery is preferred over monopolar. The monopolar grounding pad should be placed to minimize flow of electrical current through the amniotic fluid. (C)
- In late pregnancy, women should be placed in the lateral decubitus position during and after the procedure. (C)
- Although many antibiotics can be safely used in pregnancy, some are contraindicated (quinolones, streptomycin, tetracyclines), whereas others are safe only in certain stages of fetal development. (B)
- Breast-feeding may be continued after maternal fentanyl administration (B), which is preferred over meperidine. (C)
- Infants should not be breast-fed for at least 4 hours after maternal midazolam administration. (B)
- Continued breast-feeding after maternal propofol exposure is not recommended, although the period of prohibition is unknown. (C)
- Penicillins, cephalosporins, tetracyclines, and erythromycin are compatible with breast-feeding. Quinolones and sulfonamides should be avoided. (C)

Definitions

Levels of Evidence

- A. Prospective controlled trials
- B. Observational studies
- C. Expert opinion

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and classified for the recommendations using the following scheme:

- A. Prospective controlled trials
- B. Observational studies
- C. Expert opinion

When little or no data exist from well-designed prospective trials, emphasis is given to results from large series and reports from recognized experts. Guidelines for appropriate utilization of endoscopy are based on a critical review of the available data and expert consensus.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

- Appropriate and effective use of endoscopy in pregnant and lactating women
- In situations where therapeutic intervention is necessary, endoscopy offers a relatively safe alternative to radiologic or surgical intervention.

POTENTIAL HARMS

See the "Major Recommendations" for a full discussion of the potential risks of medications and endoscopic procedures in pregnant and lactating women.

CONTRAINDICATIONS

CONTRAINDICATIONS

- Naloxone is contraindicated in mothers dependent on opiates, because it can precipitate opiate-withdrawal symptoms.
- Endoscopy is contraindicated in obstetric complications such as placental abruption, imminent delivery, ruptured membranes, or eclampsia
- Sulfonamides are contraindicated when nursing infants younger than 2 months because of the risk of kernicterus. It is recommended that sulfonamides be avoided in infants that are ill, premature, and glucose-6-phosphate dehydrogenase deficient.
- Although many antibiotics can be safely used in pregnancy, some are contraindicated (quinolones, streptomycin, tetracyclines), whereas others are safe only in certain stages of fetal development.

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

- Further controlled clinical studies are needed to clarify aspects of this statement, and revision may be necessary as new data appear. Clinical consideration may justify a course of action at variance to these recommendations.
- The safety and the efficacy of gastrointestinal endoscopy in pregnant patients are not well studied. Studies involving humans tend to be small and retrospective. Much of the drug safety data is based on animal studies. Invasive procedures are justified when it is clear that by not doing so could expose the fetus and/or the mother to harm. Informed consent should include risks to the fetus as well as the mother.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Living with Illness

IOM DOMAIN

Effectiveness
Safety

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Qureshi WA, Rajan E, Adler DG, Davila RE, Hirota WK, Jacobson BC, Leighton JA, Zuckerman MJ, Hambrick RD, Fanelli RD, Baron T, Faigel DO. ASGE guideline: guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc 2005 Mar;61(3):357-62. [36 references] [PubMed](#)

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2005 Mar

GUIDELINE DEVELOPER(S)

American Society for Gastrointestinal Endoscopy - Medical Specialty Society

SOURCE(S) OF FUNDING

American Society for Gastrointestinal Endoscopy

GUIDELINE COMMITTEE

Standards of Practice Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Committee Members: Douglas O. Faigel, MD (Chair); Todd Baron, MD (Vice Chair); Waqar A. Qureshi, MD; Elizabeth Rajan, MD; Douglas G. Adler, MD; Raquel E. Davila, MD; William K. Hirota, MD; Brian C. Jacobson, MD, MPH; Jonathan A. Leighton, MD; Marc J. Zuckerman, MD; R. David Hambrick, RN, CGRN (SGNA Representative); Robert D. Fanelli, MD, FACS (SAGES Representative)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the [American Society for Gastrointestinal Endoscopy \(ASGE\) Web site](#).

Print copies: Available from the American Society for Gastrointestinal Endoscopy, 1520 Kensington Road, Suite 202, Oak Brook, IL 60523

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on April 8, 2005.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 9/25/2006

